Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents

NCT00963937 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine Disorders

Interventions

DRUG: Sumatriptan 25 mg
DRUG: Sumatriptan 50 mg
DRUG: Placebo

Sponsor

GlaxoSmithKline